Fol. Biol. 2020, 66, 86-90

https://doi.org/10.14712/fb2020066030086

Transfer Factor as an Option for Managing the COVID-19 Pandemic

D. Viza1, G. Pizza2, C. De Vinci2, G. Brandi3, Dharam Ablashi4

1Immunobiology Laboratory, Faculté de Médicine, Paris 6, France
2Immunotherapy dept., S. Orsola-Malpighi University Hospital, Bologna, Italy
3Medical Oncology, S. Orsola-Malpighi University Hospital, Bologna, Italy
4HHV-6 Foundation, Santa Barbara, CA, USA

Received June 2020
Accepted July 2020

References

1. Afari, N., Buchwald, D. (2003) Chronic fatigue syndrome: A review. Am. J. Psychiatry 160, 205-207. <https://doi.org/10.1176/appi.ajp.160.2.221>
2. Ahmed, F., Ahmed, N., Pissarides, C., Stiglitz, J., (2020) Why inequality could spread COVID-19. The Lancet 5, 5.
3. Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., Engen, W. N., Cheng M. P., LaBar, D., Lother, S. A., MacKenzie, L. J., Drobot, D., Marten, N., Zarychanski, R, Kelly, L., E., Schwartz, I., S., McDonald, E.,G., Rajasingham, R., Lee, T. C., Hullsiek, K., H. (2020) A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N. Eng. J. Med. 1, 9.
4. Buchwald, D., Freedman, A. S., Ablashi, D. V., Sullivan, J. L., Calligiuri, M., Weinberg, D. S., Hall, C. G., Bashir, R., Singer, R. M., Ashley, R. L., Saxinger, C., Balachandran, N., Ritz, J., Nadler, L. M., Komaroff, A. L. (1990) A chronic “post-infectious” fatigue associated with benign lymphoproliferation, B-cell proliferation and active replication of human herpesvirus-6. J. Clin. Immunol. 10, 335-344. <https://doi.org/10.1007/BF00917479>
5. Buchwald, D., Cheney, P., Peterson, D. L., Henry, B., Wormsley, S. B., Geiger, A., Ablashi, D. V., Salahuddin, S. Z., Saxinger, C., Biddle, R., Kilkinis, R., Jolesz, F. A., Folks, T., Balachandran, N., Gallo, R. C., Komaroff, A. L. (1992) A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus-6 infection. Ann. Intern. Med. 116, 103-113. <https://doi.org/10.7326/0003-4819-116-2-103>
6. Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., Zhang, X., Zhang, M., Wu, S., Song, J., Chen, T., Han, M., Li, S., Luo, X., Zhao, J., Ning, Q. (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620-2629. <https://doi.org/10.1172/JCI137244>
7. Chen, L., Xiong, J., Bao, L., Shi, Y. (2020) Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 20, 398-400. <https://doi.org/10.1016/S1473-3099(20)30141-9>
8. Delgado, O., Romano, E. L., Belfort, E., Pifano, F., Scorza, J. V, Rojas, Z. (1981) Dialyzable leukocyte extracts therapy in immunodepressed patients with cutaneous leishmaniasis. Clin. Immunol. Immunopathol. 19, 351-358. <https://doi.org/10.1016/0090-1229(81)90078-7>
9. Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., Peng, C., Yuan, M., Huang, J., Wang, Z., Yu, J., Gao, X., Wang, D., Yu, X., Li, L., Zhang, J., Wu, X., Li, B., Xu, Y., Chen, W., Peng, Y., Hu, Y., Lin, L., Liu, X., Huang, S., Zhou, Z., Zhang, L., Wang, Y., Zhang, Z., Deng, K., Xia, Z., Gong, D., Zhang, W., Zheng, X., Liu, Y., Yang, H., Zhou, D., Yu, D., Hou, J., Shi, Z., Chen, S., Chen, Z., Zhang, X., Yang, X. (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. USA 117, 9490-9496. <https://doi.org/10.1073/pnas.2004168117>
10. Dwyer, J. M. (1983) The use of antigen-specific transfer factor in the management of infections with herpes viruses. In: C. H. Kirkpatrick: Immunobiology of Transfer Factor, pp. 233-244. Academic Press, New York.
11. Gattinoni, L., Coppola, S., Cressoni, M., Busana, M., Rossi, S., Chiumello, D. (2020) Covid-19 does not lead to a “typical” acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 201, 1299-1300. <https://doi.org/10.1164/rccm.202003-0817LE>
12. Harahsheh, A. S., Dahdah, N., Newburger, J. W., Portman, M. A., Piram, M., Tulloh, R., McCrindle, B. W., de Ferranti, S. D., Cimaz, R., Truong, D. T., Jane C. Burns , J. C. (2020) Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. J. Pediatr. 222, 261-262. <https://doi.org/10.1016/j.jpeds.2020.04.052>
13. Kirkpatrick, C. H., (2000) Transfer factors: identification of conserved sequences in transfer factor molecules. Mol. Med. 6, 332-341. <https://doi.org/10.1007/BF03401941>
14. Klesius, P. H., Qualls, D. F., Elston, A. L., Fudenberg, H. H. (1978) Effects of bovine transfer factor (TFd) in mouse coccidiosis (Eimeria ferrisi). Clin. Imm. Immunopath. 10, 214-221. <https://doi.org/10.1016/0090-1229(78)90029-6>
15. Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., Lessler, J. (2020) The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann. Intern. Med. <https://doi.org/10.7326/M20-0504>
16. Lawrence, H. S. (1955) The transfer in humans of delayed skin sensitivity to streptococci M substance and to tuberculin with disrupted leukocytes. J. Clin. Invest. 34, 219-32. <https://doi.org/10.1172/JCI103075>
17. Levine, P. H., Pizza, G., Ajmera, K., De Vinci, C., Viza, D. (2011) Transfer factor in virus-associated malignancies: an underestimated weapon in prevention and treatment of cancer. Adv. Tumor Virol. 2, 7-20.
18. McMeeking, A., Borkowski, W., Klesius, P. H., Bonk, S., Holzman, R. S., Lawrence, H. S. (1990) A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. J. Infect. Dis. 161, 108-112. <https://doi.org/10.1093/infdis/161.1.108>
19. Mehra, M. R., Desai, S. S., Ruschitzka, F., Patel, A. N. (2020) Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet. RETRACTED.
20. Meng, H., Xiong, R., He, R., Lin, W., Hao, B., Zhang, L., Lu, Z., Shen, X., Fan, T., Jiang, W., Li, T., Chen, J., Geng, Q. (2020) CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan. J. Infect. 81, 33-39. <https://doi.org/10.1016/j.jinf.2020.04.004>
21. Myles, I. A., Zhao, M., Nardone, G., Olano, L. R., Reckhow, J. D., Saleem, D., Break, T. J., Lionakis, M. S., Myers, T. G., Gardina, P. J., Kirkpatrick, C. H., Holland, S. M., Datta, S. K. (2017) CD8+ T cells produce a dialyzable antigenspecific activator of dendritic cells. J. Leukoc. Biol. 101, 307-320. <https://doi.org/10.1189/jlb.3A0216-082R>
22. Nkrumah, F., Pizza, G., Viza, D., Phillips, J., De Vinci, C., Levine, P. (1985) Regression of progressive lymphadenopathy in a young child with acute cytomegalovirus (CMV) infection following the administration of transfer factor with specific anti-CMV activity. Lymphokine Res. 4, 237-241.
23. Pizza, G., Amadori, M., Ablashi, D., De Vinci, C., Viza, D., (2006) Cell mediated immunity to meet the avian influenza A (H5N1) challenge. Med. Hypotheses 67, 601-608. <https://doi.org/10.1016/j.mehy.2006.02.034>
24. Pizza, G., Meduri, R., De Vinci, C., Scorolli, L., Viza, D. (1995) Transfer factor prevents relapses in herpes keratitis patients: A pilot study. Biotherapy 8, 63-68. <https://doi.org/10.1007/BF01878122>
25. Popper, K. R. (1959) The Logic of Scientific Discovery. Hutchinson, London.
26. Popper, K. R. (1963) Conjectures and Refutations. Routledge and Kegan, London.
27. Popper, K.R., (1975) Objective Knowledge. Oxford University Press.
28. Prasad, U., bin Jalaludin, M. A., Rajadurai, P., Pizza, G., De Vinci, C., Viza, D., Levine, P. H. (1996) Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: A pilot study. Biotherapy 9, 109-115. <https://doi.org/10.1007/BF02628667>
29. Rasa, S., Nora-Krukle, Z., Henning, N., Eliassen, E., Shikova, E., Harrer, T., Scheibenbogen, C., Murovska, M., Bhupesh, K. P. (2018) Chronic viral infections in myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS). J. Transl. Med. 16, 268. <https://doi.org/10.1186/s12967-018-1644-y>
30. Schreiner, P., Harrer, T., Scheibenbogen, C., Lamer, S., Schlosser, A., Naviaux, R. K., Prusty, B. K. (2020) Human herpesvirus-6 reactivation, mitochondrial fragmentation, and the coordination of antiviral and metabolic phenotypes in myalgic encephalomyelitis/chronic fatigue syndrome. Immunohorizons 4, 201-215. <https://doi.org/10.4049/immunohorizons.2000006>
31. Sharma, M., Firouz, R., Ala, F. (1979a) Transfer factor therapy in human cutaneous leishmania infection (CLI): A double- blind clinical trial in immune regulators. In: Transfer Factor, eds. Khan, A., Kirkpatrick, C. H., Hill, N. O., pp. 563-570. Academic Press, N.Y.
32. Sharma, M. K., Anaraki, F., Ala, F. (1979b) Preliminary results of transfer factor therapy of persistent cutaneous leishmania infection. Clin. Immunol. Immunopathol. 12, 183-190. <https://doi.org/10.1016/0090-1229(79)90007-2>
33. Steele, R. W., Heberling, R. L., Eichberg, J. W. (1976) Prevention of herpes simplex virus type 1 fatal dissemination in primates with human transfer factor. In: Ascher, M. S., Gottlieb, A. A., Kirkpatrick, C. H.: Transfer Factor. Basic Properties and Clinical Applications, pp. 381-384. Academic Press, New York.
34. Steele, R. W., (1980) Transfer factor and cellular reactivity to varicella zoster antigen in childhood leukaemia. Cell. Immunol. 50, 282-289. <https://doi.org/10.1016/0008-8749(80)90283-X>
35. Steele, R. W., Myers, M. G., Vincent, M. M., (1980). Transfer factor for the prevention of varicella zoster infection in childhood leukaemia. N. Eng. J. Med. 303, 355-359. <https://doi.org/10.1056/NEJM198008143030702>
36. United Nations News, Department of Economic and Social Affairs. (2017) World population projected to reach 9.8 billion in 2050, and 11.2 billion in 2100. June 21, New York.
37. Viza, D., Goust, J. M., Moulias, R., Trejdosiewicz, L. K., Collard, A., Müller-Bérat, N., (1975) ‘In vitro’ production of transfer factor by lymphoblastoid cell lines. Transplant. VII (suppl. 1), 329-333.
38. Viza, D., Boucheix, C., Cesarini, J. P., Ablashi, D. V., Armstrong, G., Levine, P., Pizza, G., (1982) Characterization of a human lymphoblastoid cell line, LDV/7, used to replicate transfer factor and immune RNA. Biol. Cell. 46, 1-10.
39. Viza, D., Vich, J. M., Phillips, J., Rosenfeld, F. (1985) Orally administered specific transfer factor for the treatment of herpes infections. Lymphok. Res. 4, 27-30.
40. Viza, D., Vich, J. M., Phillips, J., Rosenfeld, F., Davies, D. A. L. (1986) Specific transfer factor protects mice against lethal challenge with herpes simplex virus. Cell. Immun. 100, 555-562. <https://doi.org/10.1016/0008-8749(86)90053-5>
41. Viza, D., Lefesvre, A., Patrasco, M., Phillips, J., Hebbrecht, N., Laumond, G., Vich, J. M., (1987) A preliminary report on three AIDS patients treated with anti-HIV specific transfer factor. J. Exp. Pathol. 3, 653-659.
42. Viza, D., Vich, J. M., Minarro, A., Ablashi, D. V., Salahuddin, S. Z. (1988) Soluble extracts from a lymphoblastoid cell line modulate SAIDS evolution. J. Virol. Methods 21, 241-253. <https://doi.org/10.1016/0166-0934(88)90070-5>
43. Viza, D., Fudenberg, H. H., Palareti, A., Ablashi, D., De Vinci, C., Pizza, G. (2013) Transfer factor: an overlooked potential for the prevention and treatment of infectious diseases. Folia Biol. (Praha) 59, 53-67.
44. Wang, F., Nie, J., Wang, H., Zhao, Q., Xiong, Y., Deng, L., Song, S., Ma, Z., Mo, P., Zhang, Y. (2020) Characteristics of peripheral lymphocyte subset alteration in COVID-19. Pneumonia J. Infect. Dis. 221, 1762-1769. <https://doi.org/10.1093/infdis/jiaa150>
45. Zheng, Y. Y., Ma, Y. T., Zhang, J. Y., Xie, X. (2020) COVID- 19 and the cardiovascular system. Nat. Rev. Cardiol. 17, 259-260. <https://doi.org/10.1038/s41569-020-0360-5>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive